Seaview Investment Managers LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 26.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,717 shares of the company's stock after buying an additional 2,675 shares during the quarter. Eli Lilly and Company accounts for approximately 2.7% of Seaview Investment Managers LLC's holdings, making the stock its 16th biggest holding. Seaview Investment Managers LLC's holdings in Eli Lilly and Company were worth $9,818,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in LLY. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock valued at $57,320,226,000 after purchasing an additional 475,530 shares during the last quarter. Geode Capital Management LLC lifted its position in Eli Lilly and Company by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock worth $13,389,651,000 after buying an additional 291,875 shares during the last quarter. Wellington Management Group LLP boosted its stake in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after buying an additional 2,012,129 shares during the period. Norges Bank bought a new position in Eli Lilly and Company during the fourth quarter valued at $8,407,908,000. Finally, Capital Research Global Investors raised its stake in shares of Eli Lilly and Company by 16.1% in the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock valued at $8,304,811,000 after acquiring an additional 1,493,673 shares during the period. Institutional investors own 82.53% of the company's stock.
Eli Lilly and Company Stock Up 0.4 %
Shares of Eli Lilly and Company stock traded up $3.03 on Wednesday, reaching $830.57. The stock had a trading volume of 2,712,395 shares, compared to its average volume of 3,427,067. The stock has a market capitalization of $787.52 billion, a P/E ratio of 70.93, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a 50 day moving average price of $827.10 and a 200 day moving average price of $818.99.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.
Insider Transactions at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.13% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research note on Tuesday. They set an "overweight" rating and a $975.00 target price on the stock. Guggenheim decreased their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Citigroup cut their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,017.00.
Get Our Latest Report on LLY
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
